Steve Vucic PhD of Neuroscience Research Australia talks about transcranial magnetic stimulation (TMS), an emerging test that may help clinicians identify people with ALS before the first symptoms of disease. Learn more: http://blogs.als.net/post/2013/06/19/TMS-a-headstart-for-PALS.aspx

Paul Gordon MD of the Indian Health Service (HIS) talks about his latest results which suggest that ALS might be less common in Native Americans. His studies may one day help identify triggers of ALS and potential ways to fight the disease.

Kirsten Gruis MD of the State University of New York talks about the NeuRX DPS, a device that aims to help people with ALS breathe better and live longer by electrically conditioning the diaphragm. Learn more: http://blogs.als.net/post/2013/05/07/The-DPS-Point-Blank.aspx

Pierre-Francois Pradat MD PhD of the Assistance Publique - Hôpitaux de Paris in France talks about GSK's potential ALS medicine ozanezumab, now at phase II. Learn more: http://blogs.als.net/post/2013/04/09/A-Go-For-anti-NOGO-A.aspx

Steve Perrin PhD, CEO and CSO of ALS TDI, talks Gilenya, other emerging immunomodulators and their potential to treat ALS going forward. Read more: http://blogs.als.net/post/2013/02/12/Gilenya-giving-ALS-the-fingo.aspx

Michael Weiss MD, Director of the Neuromuscular Diseases Division of the University of Washington School of Medicine, discusses an upcoming phase II clinical trial that puts mexiletine to the test in ALS, a potential early treatment of the disease. Read more: http://blogs.als.net/post/2013/02/05/Mexiletine-channeling-ALS.aspx

Doug Kerr MD PhD, Biogen-Idec’s Director of Neurodegenerative Research, talks dexpramipexole, the lessons learned and the development of future ALS medicines in the clinic going forward. Read more: http://blogs.als.net/post/ALS-clinical-trials-powering-forward.aspx

Robert Miller MD, Director of California Pacific Medical Center’s Forbes Norris MDA/ALS Research and Treatment Center, talks NP001 and its potential to treat ALS going forward. Read more: http://blogs.als.net/post/2012/12/17/NP001-a-quiet-riot-in-ALS.aspx

Athanase Millogo, MD of Bobo-Dioulasso University Teaching Hospital in Burkina Faso, talks TROPALS and its potential impact on people with ALS/MND in Africa going forward. Read more: http://blogs.als.net/post/2012/11/06/ALS-Out-of-Africa.aspx

Jeff Rothstein MD PhD, director of the Packard Center for ALS Research at Johns Hopkins University School of Medicine, talks C9ORF72 and potential treatments for this form of ALS going forward. Read more: http://blogs.als.net/post/2012/10/29/ALS-dressed-to-the-C9s.aspx